PerpEquities

Samsung Biologics Co., Ltd. (SSBIOLOGICS) income statement

KSC · Healthcare · Biotechnology · 5,455 employees · CEO John Chongbo Rim

Price
$1,001 -0.1%
Market cap
$48.5B
Enterprise value
₩65.5T Data as of 2026-11-21
Last report
Q3 '26 filed 2026-09-30
Next report
2027-01-27 EPS est. ₩11,137.25

Samsung Biologics Co., Ltd. (SSBIOLOGICS) reported revenue of ₩1.49T for Q3 '26 (-10.2% year on year), operating income of ₩640B (43.0% of revenue) and net income of ₩391B. Over the last four quarters revenue was ₩4.38T.

Income statement

Income statementTrendQ4 '23Q1 '24Q2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Revenue₩1.07T₩947B₩1.16T₩1.19T₩1.26T₩1.3T₩1.29T₩1.66T₩309B₩1.26T₩1.32T₩1.49T
Cost of revenue₩551B₩536B₩509B₩659B₩601B₩543B₩586B₩645B₩223B₩555B₩599B₩752B
Gross profit₩522B₩410B₩648B₩528B₩655B₩755B₩704B₩1.01T₩86B₩702B₩722B₩1.49T
Research & development₩22.4B₩24.6B₩26.6B₩29.6B₩63.9B₩87.1B₩40.3B₩107B₩0₩38.2B₩0₩0
General & administrative₩0₩0₩0₩0₩0₩0₩0₩0₩0₩0₩0₩98.4B
Other operating expenses₩886M₩1.71B₩6.12B₩1.61B₩1.7B₩1.67B₩8.78B₩598M-₩5.08B₩578M₩135B₩752B
Operating expenses₩172B₩189B₩213B₩190B₩329B₩268B₩228B₩286B-₩5.08B₩122B₩135B₩850B
Operating income₩350B₩221B₩435B₩339B₩326B₩487B₩476B₩729B₩91.1B₩581B₩586B₩640B
Interest income₩25.6B₩22.4B₩14.4B₩13.3B₩13.7B₩13.2B₩12.4B₩13.4B₩7.08B₩14B₩13.3B₩19.3B
Interest expense₩19.5B₩16.1B₩8.18B₩1.73B₩24.1B₩9.92B₩8.26B₩10.7B₩285M₩7.15B₩8.78B₩9.46B
Other non-operating income (gains on investments, FX ...)-₩25.2B-₩34.9B-₩38.6B₩45.9B-₩72.4B-₩22.6B₩58.4B-₩48.9B-₩353B-₩67B₩0₩108B
Total non-operating income₩5.74B₩18.8B₩30.4B-₩47.6B₩48.4B₩12.7B-₩66.7B₩38.2B₩352B₩59.8B-₩1.8B-₩108B
Income before tax₩356B₩240B₩465B₩291B₩374B₩499B₩409B₩767B₩443B₩641B₩585B₩532B
Income tax₩65B₩60.7B₩147B₩26.5B₩52.5B₩124B₩84.5B₩193B₩103B₩171B₩154B₩141B
Net income₩291B₩179B₩318B₩264B₩321B₩376B₩324B₩574B₩510B₩469B₩431B₩391B
EPS (basic)₩6,279.49₩3,874.66₩6,869.42₩5,713.18₩6,945.06₩8,112.89₩7,007.55₩12,409.00₩11,028.00₩10,148.00₩9,304.19₩8,391.77
EPS (diluted)₩6,279.49₩3,874.66₩6,869.42₩5,713.18₩6,945.06₩8,112.89₩7,007.55₩12,409.00₩11,028.00₩10,148.00₩9,304.19₩8,391.77
Shares (basic, weighted)46.3M46.3M46.3M46.3M46.3M46.3M46.3M46.3M46.2M46.2M46.3M46.6M
Shares (diluted, weighted)46.3M46.3M46.3M46.3M46.3M46.3M46.3M46.3M46.2M46.2M46.3M46.6M
Depreciation & amortization₩142B₩143B₩148B₩157B₩151B₩163B₩178B₩179B₩113B₩94.6B₩112B₩111B
EBITDA₩517B₩400B₩621B₩450B₩549B₩673B₩595B₩957B₩557B₩742B₩699B₩532B

Standardised from the company's filings; outflows and costs keep the sign the provider reports. Hover a period for its end date. Amounts in KRW.

Revenue, operating income and growth

quarterly

Margins

quarterly

Costs as % of revenue

quarterly

The other statements

Sources

Statements, segment revenue, metrics and estimates are standardised from the company's filings.

Data as of 2026-11-21 · Amounts in KRW as reported; price and market cap in USD.